Skip to search
Skip to main content
Back to Search
Start Over
Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
Authors :
Garcia-Manero, Guillermo Fenaux, Pierre Al-Kali, Aref Baer, Maria R. Sekeres, Mikkael A. Roboz, Gail J. Gaidano, Gianluca Scott, Bart L. Greenberg, Peter L. Platzbecker, Uwe Steensma, David P. Kambhampati, Suman Kreuzer, Karl-Anton Godley, Lucy A. Collins, Robert Atallah, Ehab Wilhelm, Francois Wilhelm, Isabelle E. Azarnia, Nozar Maniar, Manoj Silverman, Lewis R. Garcia-Manero, Guillermo Fenaux, Pierre Al-Kali, Aref Baer, Maria R. Sekeres, Mikkael A. Roboz, Gail J. Gaidano, Gianluca Scott, Bart L. Greenberg, Peter L. Platzbecker, Uwe Steensma, David P. Kambhampati, Suman Kreuzer, Karl-Anton Godley, Lucy A. Collins, Robert Atallah, Ehab Wilhelm, Francois Wilhelm, Isabelle E. Azarnia, Nozar Maniar, Manoj Silverman, Lewis R.
Publication Year :
2014
Details
Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1247373251
Document Type :
Electronic Resource